Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CD: Took a nibble of AMFE but it does look quite risky.
Not quite as risky and also growing fast is NVTA.
PACB is interesting, if less exciting.
IONS is sorta like SGEN in prospects.
A conservative investor would touch none of them...grin.
Thanks C Daniel:
I'll give AMFE a good gander.
With all their drugs in testing or trials, a big pipeline, and the first of them FDA approved, the technology proved valid...It's reasonable to hope that SGEN will pay for your whole house quite nicely.
(Good attitude , huh).
Kettleman; I think that when we bought FSYS, we acquired a segment that makes NG systems for smaller vehicles.
Don't know if we still have that part.
The car next to my truck at the blacksmith's conference last weekend was a newer GM electric.
We were camping under the redwoods and he had the hood up and cables running to his buddy's vehicle most of the time. He missed the main demonstrator and drove 400 miles to work on his car.
Further, he had to cover much of the distance powered by the little gas engine under the hood.
We live way out in the boonies, frequently haul considerable weight, and an electric car is not in our future yet.
Sorry, wasn't paying attention to the time line, as usual.
Now that we passed $3, my charting clearly indicates
that the company is going to mail out paper party hats
and noise makers.
PS, that wasn't luck!
Well done sir!
Now that we've passed $3, Jack must be shorting again....
I'll nod respectfully but not wish him good luck on that.
nope,
"Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS(R) (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma"
Daniel, check out the stock news before asking please.
Hodgkins is a rather popular disease with very serious consequences and the treatments have had nasty side effects.
Hi DW:
Not bailing out of that miasma of despair took real stupid stubborness, a quality i'm strong on.
Having bought in in the heady days before the collapse of fuel prices (around $12?) i'm still orders of magnitude under water here.
But i did average down some, which might help.
I bought the left stern quarter of Jack's boat, i suspect.
Recently we were down around a buck a share and i said it was Cheap.
If you'd bought then, you could have tripled your money.
But at $3, it's still really cheap.
With the huge deals in China, the future of the company looks very bright.
Buy all you can and just sit on it..There's real $ to be made if you can be patient for a few years.
Smasse:
The market for ADXS is fast falling under the pall of the forces of deregulation, as they dominate in the legal arena.
The time to appeal to the overwhelmed SEC is past.
These manipulated market swings are only going to get more extreme.
Either we figure out how to take advantage of them or only play the market on a very long term scale. It's much easier for us little guys to get crushed now.
Qcom extended the offer again.
Suspect they are just waiting for a short term crash in our SP to fill in their required # of shares.
Have to wonder if they are above initiating that crash?
Perhaps if they can write the deal to cover only one indication and make sure to get a decent royalty. Also a guarantee that the purchaser won't just shelve it but would push forward with trials and approval.
BP is not above buying a controlling interest in a potentially competing drug, then quietly shelving it.
Bourbon: Those early trials are fairly inexpensive.
One failure was qualitative control on the India trial and on the other "deals" made..Weak or unenforceable contracts apparently.
Yes, we agree, we should have focused all our resources on pushing the strongest constructs through FDA approval.
We had enough $ to get through a phase 3 trial at one point, and good candidates for that.
Instead we spent it on administration, Buildings and a manufacturing facility, dog and pony presentations and assorted diversions and insupportable executive compensation.
Instead of a vital, life saving company, thousands have died agonizing deaths while management kept themselves comfy.
As an investor at $14 pre reverse split and as a metastasized cancer survivor..I'm really very angry.
Thanks Ignatious:
Admittedly pediatric is tricky and was probably chosen for it's emotional appeal ( wryly, if it works on dogs, why not kids?)
So how bout the terrible but ever so popular HER breast cancer? Probably much easier to get funding and popular support for.
How bout selling the anal cancer construct instead, where our neglected first little trial yielded 100% response rate?
Hi Lorema:
If the canine osteosarcoma is near approval, as we've believed for much too long to be taken seriously, then that approval would be a significant validation for the HER construct and enhance it's and our value....Validation we are hard up for.
I like your armpit analogy.
Marine Harvest , based in Norway, raises salmon in pens in oceans around the world.
They pay a plump dividend and the PPS has appreciated very nicely since i bought in.
One of the posters here on the Hub pointed me to it and i'd like to thank him...Can't remember his/her name.
I'm a bit ambivalent about farmed salmon. The operations have some negative environmental impact in terms of concentrated effluent and catching wild fish to feed them. Also, with the fish crowded together they are prone to various ailments and often must be medicated.
Last, there is risk similar to any sort of farming operation.
But folks gotta eat and your doctor says salmon belongs on your dinner plate.
Hi Ignatious:
Even the doddering FDA is coming to recognize that the organ of origin of a cancer is less pertinent to it's treatment than the critical mutation that drives it.
HER mutation is the primary problem with a wide range of intractable cancers and represents no dinky niche market.
Sigh...Same thing with ADXS that i've been into much deeper for a lot longer. They dumped a lackluster CEO and the SP dropped dramatically.
We do still have clinical trials in progress, and in oncology those progress slowly so long periods go by without obvious progress and the PPS slumps.
if there's a chance, we just have to sit it out and complain to pass the time.
Thanks Capecod.
Raja:
Oh, it's at least a couple of threads surely.
I first bought at around $14 pre reverse split.
As i see it, management has and continues to squander our brilliant IP.
NEO and HOT face the proverbial 10 to 1 odds against FDA approval and if we finally get it it's probably at least 7 years away....More by ADXS standards of progress.
OTOH, eventually, the clinical trials now in progress will run their course and if the results are decent, the SP will soar again.
Like most small clinical stage bios, the PPS rides the yoyo graph between announcements of significant progress.
We have been waiting with stale baited breath for the canine osteosarcoma approval. If that finally happens, dropping the HER effort is going to seem stupid.
I presume that means Lombardo has learned that the canine deal is dead in the water and that trickle of hope has dried up.
Lombardo does not seem eager to push our constructs forward as briskly as needed, much like his predecessor.
He was appointed as interim CEO and i sincerely hope we can replace him with someone much more science oriented and a more aggressive and adroit manager.
Meanwhile, we tread water.
Time to invest in lithium and rare earths again then?
Keep seeing research articles about a cheaper, more recyclable, vehicle battery that's 1/2 the weight and handles twice the charge.
If that finally becomes available, it'll decide the matter.
Still going to be a lot of years before hydrogen is practical and competitive.
It's tricky to handle , hard to contain and unforgivingly explosive.
China is still running and building dirty coal generating plants too, as well as NG plants.
It's gonna take a whole lot of solar panels to replace them.
Jack both hydrogen and electricity most often require fossil fuel to generate and are therefore generally not zero emission with a few small but growing exceptions ( hydro, solar and wind).
Up 9% on denied takeover chatter.
That was , admittedly, an optimistic interpretation.
Only been in TPIV a couple of years Marv, but i've been deeply mired in a couple of similar little underperforming bios with encouraging science but dismal management for roughly your 15 years.
I'm a sucker for a good science story. Every now and then it works out splendidly. All in all i'm about even, not counting inflation.
That would explain the paucity of postings.
Please let me know if you find one Capecod.
( i'm not far from Big Sur on the other side of the continent.)
"..Looks like Morgan Stanley, who put this deal together couldn't get many interested at the Morgan stanley event. Unreal"
Inferring it's apt to fall apart? That'd be fine with me.
We now own the tool and we better learn how to profit from it soon.
Any time us little guys dance with a huge partners, we can kiss our toes goodby, or at least at risk. We are disposable in their eyes.
Thanks once again Paulie; another significant posting..
It helps make wallowing around in the Hub worthwhile.
PACB is working to make sequencing much more meaningful and accurate.
Trying to figure out the meanings of little fragments of a whole huge genome has been an exercise in frustration.
Oh Maple; I've been under water here for a long time..A mere 60%!
How lucky for you.
I got suckered by a fine science story, ignored poor management quality, and have paid profoundly for that.
Our splendid science is aging fast . How much of our precious IP has expired?
I've sunk more % in ADXS than any other holding ,but it's pretty far down the list in value now.
If they are extending an oncology clinical trial,
it infers more patients are surviving for longer than anticipated.
That's good!
That's cause both outfits had wonderful early results and fine stories characterized by great hope...
And have been riding on that for years on end,
unwilling to spend the money and take the risks necessary
to bring their primary product to market.
AVXL being the worst of the 2 and both have sure cost me dearly.
""ADXS has same market cap as AVXL now.
Ouchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh "
SD21, you seem pretty new here.
Look, this kind of drop always happens when there is a long stretch between strong positive announcements, news or prominent articles...Same old thing.
NOW is the time to put up shares and patiently wait.